Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NF1
REST API REST API
Homo sapiens
NF1 is differentially expressed in 367 experiments: 180 organism parts: liver, bone marrow, ... (178 more);, 275 disease states: normal, breast carcinoma, ... (273 more);, 114 cell types 502 cell lines 51 compound treatments and 90 other conditions.
Orthologs NF1 (Bos taurus)   IRA1 (Saccharomyces cerevisiae)   NF1 (2 of 2) (Danio rerio)   ENSCING00000003511 (Ciona intestinalis)   Nf1 (Mus musculus)   nf1a (Danio rerio)   IRA2 (Saccharomyces cerevisiae)   ENSCING00000017301 (Ciona intestinalis)   NF1_RAT (Rattus norvegicus)   ENSCING00000017469 (Ciona intestinalis)   NF1 (Gallus gallus)   Nf1 (Drosophila melanogaster)   nf1 (Xenopus laevis)   ENSXETG00000034345 (Xenopus laevis)   NF1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term Ras GTPase activator activity, protein binding, axon, visual learning, cytoplasm, positive regulation of adenylate cyclase activity, regulation of cell proliferation, intracellular, regulation of cell-matrix adhesion, negative regulation of cell proliferation, negative regulation of protein kinase activity, wound healing, MAPKKK cascade, negative regulation of Ras protein signal transduction, response to hypoxia, positive regulation of apoptosis, cell communication, negative regulation of neuroblast proliferation, GTPase activator activity, actin cytoskeleton organization, Ras protein signal transduction, nucleus, heart development, negative regulation of cell migration, regulation of small GTPase mediated signal transduction, dendrite, negative regulation of transcription factor import into nucleus, negative regulation of MAP kinase activity, negative regulation of MAPKKK cascade, extracellular matrix organization, negative regulation of Rac protein signal transduction, brain development, skeletal muscle tissue development, signal transduction, peripheral nervous system development, regulation of blood vessel endothelial cell migration, forebrain morphogenesis, regulation of angiogenesis, negative regulation of fibroblast proliferation, negative regulation of oligodendrocyte differentiation, regulation of long-term neuronal synaptic plasticity, cognition, negative regulation of angiogenesis, collagen fibril organization, adrenal gland development, regulation of Ras GTPase activity, spinal cord development, cerebral cortex development, camera-type eye morphogenesis, negative regulation of osteoclast differentiation, positive regulation of Ras GTPase activity, osteoblast differentiation, negative regulation of neurotransmitter secretion, pigmentation, metanephros development, regulation of glial cell differentiation, Schwann cell development, smooth muscle tissue development, regulation of bone resorption, sympathetic nervous system development, neural tube development, negative regulation of astrocyte differentiation, artery morphogenesis, regulation of synaptic transmission, GABAergic, liver development, positive regulation of endothelial cell proliferation, positive regulation of neuron apoptosis, negative regulation of cell-matrix adhesion, forebrain astrocyte development, negative regulation of endothelial cell proliferation, myelination in peripheral nervous system, intrinsic to internal side of plasma membrane, phosphatidylinositol 3-kinase cascade
InterPro Term RasGAP, CRAL-bd_TRIO_C
Gene-Disease Assocation WATSON SYNDROME, NEUROFIBROMATOSIS, FAMILIAL SPINAL, COLORECTAL CANCER; CRC, JUVENILE MYELOMONOCYTIC LEUKEMIA; JMML, NEUROFIBROMATOSIS, TYPE I; NF1, NEUROFIBROMATOSIS-NOONAN SYNDROME; NFNS
UniProt Accession Q9UMU3, Q4W6X4, P21359, B4DXH1, B4DXP1, Q14931, E1P657
Search EB-eye ENSG00000196712
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (48 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-3529, E-GEOD-19639, E-GEOD-5823
SW480
4
E-MEXP-1014, E-GEOD-18005, E-MTAB-37, E-GEOD-2509
H441
2
E-GEOD-16194, E-MTAB-62
BT-474
2
E-GEOD-5823, E-GEOD-3529
T84
2
E-GEOD-1474, E-MTAB-37
A549
2
E-GEOD-3202, E-GEOD-6013
496 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-TABM-34, ... (56 experiments)

Factor Value U/D Experiments
centroblast
2
E-GEOD-15271, E-TABM-702
CD34+
2
E-TABM-145, E-AFMX-5
not specified
2
E-GEOD-18811, E-GEOD-11755
CD14+ monocyte
1
2
E-AFMX-5, E-MEXP-1600, E-TABM-145
CD3- CD56bright CD62L+ NK cell
1
E-GEOD-21774
secretory cell
1
E-GEOD-3998
108 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (72 experiments)

Factor Value U/D Experiments
cervical carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-5823
lung adenocarcinoma
3
E-MEXP-231, E-MTAB-62, E-MTAB-37
multiple myeloma
3
E-MTAB-62, E-GEOD-6691, E-GEOD-2113
dermatomyositis
2
E-GEOD-1551, E-GEOD-5370
adrenocortical adenoma
2
E-TABM-311, E-GEOD-10927
myeloma
2
E-MTAB-37, E-MTAB-372
269 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-4668, E-GEOD-5258, E-GEOD-1417, E-TABM-782, ... (32 experiments)

Factor Value U/D Experiments
none
5
11
E-GEOD-5824, E-GEOD-20719, E-GEOD-412, E-GEOD-1417, E-TABM-868, ... (16 experiments)
endotoxin
2
E-GEOD-2322, E-GEOD-3026
control
2
E-GEOD-3284, E-GEOD-5339
U0126
1
E-GEOD-697
hydroxyurea
1
E-GEOD-571
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
45 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
48
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-4619, E-GEOD-1563, E-GEOD-21589, ... (15 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-2509, E-GEOD-22148, ... (9 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (10 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (18 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-MEXP-1273, E-TABM-263, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-GEOD-21653, E-TABM-276, E-GEOD-20194, ... (6 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (45 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400, ... (7 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-22541, E-GEOD-1561, ... (6 experiments)

Vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.473 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM